The UK’s Cambridge-based biopharma company AstraZeneca will be delivering 500,000 more doses of AZD7442 to the US after having modified an existing agreement with the US Government. AstraZeneca’s
The post AstraZeneca to deliver 500,000 more doses of AZD7442 to the US appeared first on Pharmaceutical Business review.
This is not a CAPTIS article. Originally, it was published here.